Spatial co-localization work in Merkel Cell Carcinoma accepted to USCAP 2018

Our work with Dr. Phyu Aung, Dr. Michael Tetzlaff (Dept. of Pathology, M.D Anderson Cancer Center) and Dr. Ignacio Wistuba’s lab (Dept. of Translational Molecular Pathology) on studying the co-localization of B7-H3 expression in endothelial cells of Merkel Cell Carcinoma (MCC) patients, has been accepted as an abstract to the prestigious United States and Canadian Academy of Pathology (USCAP) Annual Meeting in March 2018. MCC is a very aggressive form of skin cancer, and patient response is closely linked to immune system integrity. The B7-H3 biomarker has been shown to be a potent inhibitor of the human body’s immune response. We used our novel spatial infiltration metric on multiplexed Immunofluorescence images of resected MCC tumors, to compute the extent of B7-H3 expression in endothelial cells. This quantification enables us to now directly study the impact of B7-H3 colocalization on patient outcome, potentially allowing us to design optimal immunotherapy regimens for individual patients with MCC!!

Radiomics based ORN prediction work accepted in ASTRO-HNC 2018

Our work with Dr. Hesham Elhalawani (Dept. of Radiation Oncology, M.D Anderson Cancer Center) on early prediction of Osteo-radio-necrosis (ORN) using radiomics has been accepted to the American Society for Radiation Oncology’s Head and Neck cancer (ASTRO-HNC) symposium in 2018. We show that a functional principal component analysis (FPCA) of radiomic features extracted at multiple time points before and after radiotherapy, can predict for ORN development in patients. We significantly outperform prediction models based on pre-radiotherapy images and delta radiomics (current practice). We envisage our FPCA screening tool can be used by radiologists to optimize radiation plan for patients undergoing radiotherapy!